Image

Melanoma Research

Featured image for “The FDA Approval of TIL Therapy and What it Means for Advanced Melanoma”
03/15/2024

The FDA Approval of TIL Therapy and What it Means for Advanced Melanoma

An exciting new development in melanoma treatment is the recent FDA approval of Lifileucel (AMTAVGI) therapy, which harnesses the power…
Blog - Melanoma360
Breaking News
Melanoma Research
Featured image for “Iovance Biotherapeutics Announces Approval for TIL Therapy”
02/17/2024

Iovance Biotherapeutics Announces Approval for TIL Therapy

The Food and Drug Administration approval provides another option for advanced, refractory melanoma February 16, 2024 (Richmond, California) The FDA…
Blog - Melanoma360
Breaking News
Melanoma Research
Featured image for “FDA Approves First AI-Powered Skin Cancer Diagnostic Tool”
01/18/2024

FDA Approves First AI-Powered Skin Cancer Diagnostic Tool

FDA Approves First AI-Powered Skin Cancer Diagnostic Tool The DermaSensor device demonstrates a high rate of sensitivity in the detection…
Blog - Melanoma360
Breaking News
Melanoma Research
Featured image for “Immunocore Presents Three-Year Overall Survival Data from the KIMMTRAK Phase 3 Trial”
10/23/2023

Immunocore Presents Three-Year Overall Survival Data from the KIMMTRAK Phase 3 Trial

Immunocore presents three-year overall survival data from the KIMMTRAK Phase 3 trial Published: Oct 21, 2023 Data published in New…
Blog - Melanoma360
Breaking News
Melanoma Research
Featured image for “Opdivo® (nivolumab) Approved as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma”
10/15/2023

Opdivo® (nivolumab) Approved as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma

October 13, 2023 17:30 ET| Source: Bristol Myers Squibb In the Phase 3 CheckMate -76K trial, Opdivo demonstrated a statistically significant…
Blog - Melanoma360
Breaking News
Melanoma Research
Featured image for “Notes from the Lab: Novel targets for immune checkpoint inhibitors”
09/17/2023

Notes from the Lab: Novel targets for immune checkpoint inhibitors

By Paul Bunk, Ph.D. candidate, Cold Springs Harbor Laboratory Survival rates of patients with melanoma have drastically improved in the…
Blog - Melanoma360
Melanoma Research
Featured image for “Clinical Trials Catch Up”
08/15/2023

Clinical Trials Catch Up

Welcome to our new interview series called Clinical Trials Catch Up, an article delivered in a question-and-answer format designed to…
Blog - Melanoma360
Melanoma Research
Featured image for “AIM’s Latest Newsletter: The Research Edition, July 2023”
08/01/2023

AIM’s Latest Newsletter: The Research Edition, July 2023

This month’s newsletter focuses on the latest news and scientific breakthroughs in melanoma research. This edition features: Letter from AIM’s…
Blog - Melanoma360
Melanoma Research
Featured image for “Iovance Biotherapeutics Announces U.S. Food and Drug Administration Acceptance of the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma”
05/30/2023

Iovance Biotherapeutics Announces U.S. Food and Drug Administration Acceptance of the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma

May 26, 2023 17:30 ET| Source: Iovance Biotherapeutics, Inc. Priority Review Granted with Prescription Drug User Fee Act (PDUFA) Action Date…
Blog - Melanoma360
Breaking News
Melanoma Research
Featured image for “U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application and European Medicines Agency Validates Application for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma”
02/28/2023

U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application and European Medicines Agency Validates Application for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma

February 28, 2023 | Source: PRINCETON, N.J.–(BUSINESS WIRE)–  The applications are based on results from the Phase 3 CheckMate -76K trial,…
Blog - Melanoma360
Breaking News
Melanoma Research
03/15/2024

The FDA Approval of TIL Therapy and What it Means for Advanced Melanoma

An exciting new development in melanoma treatment is the recent FDA approval of Lifileucel (AMTAVGI) therapy, which harnesses the power…
Featured image for “The FDA Approval of TIL Therapy and What it Means for Advanced Melanoma”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
02/17/2024

Iovance Biotherapeutics Announces Approval for TIL Therapy

The Food and Drug Administration approval provides another option for advanced, refractory melanoma February 16, 2024 (Richmond, California) The FDA…
Featured image for “Iovance Biotherapeutics Announces Approval for TIL Therapy”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
01/18/2024

FDA Approves First AI-Powered Skin Cancer Diagnostic Tool

FDA Approves First AI-Powered Skin Cancer Diagnostic Tool The DermaSensor device demonstrates a high rate of sensitivity in the detection…
Featured image for “FDA Approves First AI-Powered Skin Cancer Diagnostic Tool”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
10/23/2023

Immunocore Presents Three-Year Overall Survival Data from the KIMMTRAK Phase 3 Trial

Immunocore presents three-year overall survival data from the KIMMTRAK Phase 3 trial Published: Oct 21, 2023 Data published in New…
Featured image for “Immunocore Presents Three-Year Overall Survival Data from the KIMMTRAK Phase 3 Trial”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
10/15/2023

Opdivo® (nivolumab) Approved as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma

October 13, 2023 17:30 ET| Source: Bristol Myers Squibb In the Phase 3 CheckMate -76K trial, Opdivo demonstrated a statistically significant…
Featured image for “Opdivo® (nivolumab) Approved as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
09/17/2023

Notes from the Lab: Novel targets for immune checkpoint inhibitors

By Paul Bunk, Ph.D. candidate, Cold Springs Harbor Laboratory Survival rates of patients with melanoma have drastically improved in the…
Featured image for “Notes from the Lab: Novel targets for immune checkpoint inhibitors”
Blog - Melanoma360
 | 
Melanoma Research
08/15/2023

Clinical Trials Catch Up

Welcome to our new interview series called Clinical Trials Catch Up, an article delivered in a question-and-answer format designed to…
Featured image for “Clinical Trials Catch Up”
Blog - Melanoma360
 | 
Melanoma Research
08/01/2023

AIM’s Latest Newsletter: The Research Edition, July 2023

This month’s newsletter focuses on the latest news and scientific breakthroughs in melanoma research. This edition features: Letter from AIM’s…
Featured image for “AIM’s Latest Newsletter: The Research Edition, July 2023”
Blog - Melanoma360
 | 
Melanoma Research
05/30/2023

Iovance Biotherapeutics Announces U.S. Food and Drug Administration Acceptance of the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma

May 26, 2023 17:30 ET| Source: Iovance Biotherapeutics, Inc. Priority Review Granted with Prescription Drug User Fee Act (PDUFA) Action Date…
Featured image for “Iovance Biotherapeutics Announces U.S. Food and Drug Administration Acceptance of the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
02/28/2023

U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application and European Medicines Agency Validates Application for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma

February 28, 2023 | Source: PRINCETON, N.J.–(BUSINESS WIRE)–  The applications are based on results from the Phase 3 CheckMate -76K trial,…
Featured image for “U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application and European Medicines Agency Validates Application for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research